



Dr. Reddy's Laboratories Ltd.  
8-2-337, Road No. 3, Banjara Hills,  
Hyderabad - 500 034, Telangana,  
India.  
CIN : L85195TG1984PLC004507

Tel : +91 40 4900 2900  
Fax : +91 40 4900 2999  
Email : mail@drreddys.com  
www.drreddys.com

June 9, 2018

Corporate Relationship Department  
BSE Limited  
Dalal Street, Fort  
Mumbai – 400 001  
Fax Nos.: 022-22723121 / 22723719 /  
22722037 / 22722039

National Stock Exchange of India Ltd.  
“Exchange Plaza”  
Bandra-Kurla Complex, Bandra (East),  
Mumbai – 400 051  
Fax Nos.: 022-26598120/ 26598237/  
26598238

**Scrip Code: 500124**

**Scrip Code: DRREDDY-EQ**

Dear Sirs,

**Sub: Press Release**

Please find enclosed a Press Release on “**Dr. Reddy's Laboratories Limited to present at the Goldman Sachs 39th Annual Global Healthcare Conference**”.

This is for your information.

With regards,

  
Vikas Sabharwal  
Assistant Company Secretary

CC:- New York Stock Exchange Inc.(Stock Code: RDY)

**DR. REDDY'S LABORATORIES LTD.**

8-2-337, Road No. 3, Banjara Hills,  
Hyderabad - 500034. Telangana, India.

CONTACT

INVESTOR RELATIONS

MEDIA RELATIONS

SAUNAK SAVLA  
[sauunks@drreddys.com](mailto:sauunks@drreddys.com)  
(Ph: +91-40-49002135)

CALVIN PRINTER  
[calvinprinter@drreddys.com](mailto:calvinprinter@drreddys.com)  
(Ph: +91-40- 49002121)

**Dr. Reddy's Laboratories Limited to present at the  
Goldman Sachs 39<sup>th</sup> Annual Global Healthcare Conference**

Hyderabad, India, June 9<sup>th</sup>, 2018

For Immediate Release

Hyderabad, India and Princeton, NJ, USA. June 9<sup>th</sup>, 2018 — Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be presenting at the Goldman Sachs 39<sup>th</sup> Annual Global Healthcare Conference on Wednesday, June 13<sup>th</sup>, 2018, in California.

Alok Sonig, CEO, Developed Markets (North America, Europe, Japan) will present at Fireside Chat session at 8:00 a.m. PST [8:30 p.m. IST on June 13<sup>th</sup>, 2018].

Presentation material will be available on the Company's website [www.drreddys.com](http://www.drreddys.com)



**About Dr. Reddy's:** Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, Russia & CIS and India. For more information, log on to: [www.drreddys.com](http://www.drreddys.com)

**Disclaimer:** This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.

The company assumes no obligation to update any information contained herein.